Adverse Effects Cause Varenicline Discontinuation: A Meta-Analysis
Aaron D Drovandi1, Carla C Chen, Beverley D Glass
1Room 031, Building 47, James Cook University, Townsville, 4811, Australia. aaron.drovandi@jcu.edu.au.
Current Drug Safety
|September 29, 2015
Summary
Varenicline aids smoking cessation but adverse effects increase discontinuation. Managing side effects like nausea and insomnia is crucial for sustained abstinence and improved quit rates.
Area of Science:
- Pharmacology
- Clinical Trials
- Public Health
Background:
- Varenicline is a key pharmacotherapy for smoking cessation.
- Its efficacy is established, but adverse effects may impact treatment adherence and success.
- Understanding the link between side effects and discontinuation is vital for optimizing smoking cessation strategies.
Purpose of the Study:
- To examine the frequency and impact of adverse effects associated with varenicline treatment.
- To determine if adverse events lead to premature discontinuation of varenicline therapy.
- To assess the effect of discontinuation on smoking cessation rates.
Main Methods:
- Systematic review and meta-analysis of Randomized Controlled Trials (RCTs).
- Inclusion criteria: varenicline vs. placebo, minimum 3-month follow-up, moderate nicotine dependence (FTND score ≥5).
- Searched databases: PubMed, Medscape, JCU One Search, ClinicalTrials.gov, Cochrane Collaboration (Jan 2006-Jan 2015).
Main Results:
- 12 RCTs involving 5,459 patients were analyzed.
- Varenicline users were nearly twice as likely to experience adverse effects (OR=1.82) compared to placebo.
- Discontinuation rates were 1.5 times higher in the varenicline group (OR=1.47); nausea, insomnia, and headache were most common.
Conclusions:
- Adverse effects are significantly associated with varenicline discontinuation.
- Higher discontinuation rates likely reduce overall smoking cessation success.
- Strategies to mitigate adverse effects are needed to improve patient adherence and long-term abstinence.
Related Concept Videos
01:19Pharmacovigilance
1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K
01:30Combined Effects of Drugs: Antagonism
12.4K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
12.4K
01:23Drugs Acting on Autonomic Ganglia: Stimulants
2.3K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.3K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.8K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.8K
01:20Desensitization and Tachyphylaxis
3.4K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.4K
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
849
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
849